title: [Implementation of thrombolysis in acute stroke--10-year results of the Innsbruck stroke registry].
abstract: BACKGROUND
  Randomized controlled trials have yielded evidence for the efficacy and safety of intravenous alteplase in the therapy of acute ischemic stroke. A large patient registry has recently confirmed the safe implementation of this therapy in the clinical routine setting.
  
  
  METHODS
  Between January 1998 and December 2007 302 stroke patients were treated with 0.9 mg/kg rt-PA at the stroke unit of the Innsbruck University Hospital. Severity and circumstances of the stroke event, indicators of pre- and intrahospital management as well as safety and outcome at three months were prospectively assessed in the local thrombolysis database.
  
  
  RESULTS
  The number of patients receiving intravenous thrombolysis increased continuously from 2 patients in 1998 to 67 in 2007 and 87 patients in 2008. 43% of our patients were females. The median age and NIHSS-score on admission was 67 and 16, respectively. The mean onset-to-needle time decreased from 171 min to 110 min--mainly due to a substantial shortening of the door-to-needle time from 105 min to 45 min. A proportion of 41% of our patients were treated in the main working time while 59% received rt-PA during night and weekend service. A total of 38% of our patients were functionally independent at three months (mRS 0-2). Once considering the high initial stroke severity in our patient series and correcting the NIHSS scores to levels usually seen in randomized control trials and patient registries, 56% of our patients would reach a good outcome (mRS 0-2). The rate of symptomatic intracranial bleedings was low at 6.3%.
  
  
  CONCLUSIONS
  Our data reinforce that intravenous thrombolysis is safe in the treatment of acute ischemic stroke in clinical routine setting. Establishment of modern stroke services and the implementation of structural operating procedures have contributed to an increase in the number of treated patients and a parallel decrease in door-to-needle time at our hospital. Widespread educational programs in the general community, introduction of optimized pre-hospital triage algorithms as well as the potential extension of the 3-hour window to 4.5 hours all are suitable measures to further extend the benefit of i.v. thrombolysis to large proportion of stroke patients.
authors.affiliation: Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Austria.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Matosević
authors.forename: Alexandra
authors.initials: A
authors.lastname: Zangerle
authors.forename: Martin
authors.initials: M
authors.lastname: Furtner
authors.forename: Michael
authors.initials: M
authors.lastname: Knoflach
authors.forename: Philipp
authors.initials: P
authors.lastname: Werner
authors.forename: Barbara
authors.initials: B
authors.lastname: Prantl
authors.forename: Georg
authors.initials: G
authors.lastname: Wille
authors.forename: Arne
authors.initials: A
authors.lastname: Illmer
authors.forename: Artur
authors.initials: A
authors.lastname: Mair
authors.forename: Michael
authors.initials: M
authors.lastname: Spiegel
authors.forename: Christoph
authors.initials: C
authors.lastname: Schmidauer
authors.forename: Martin
authors.initials: M
authors.lastname: Sojer
authors.forename: Armin
authors.initials: A
authors.lastname: Muigg
authors.forename: Johann
authors.initials: J
authors.lastname: Willeit
authors.forename: Stefan
authors.initials: S
authors.lastname: Kiechl
mesh_terms: D000328:Adult; D000368:Aged; D001317:Austria / Q000453:epidemiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology*; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator